Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE001/Prednisone Plus Afuresertib in mCRPC
NCT04060394Phase 2Completed
- Sponsor
- Laekna
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of CFG920, afuresertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Laekna. Started Sep 2019; status: completed.
02
Drugs
CFG920afuresertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04060394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060394.